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The gastrin-releasing peptide receptor (GRPR)
was implicated for the first time in the pathogen-
esis of Autism spectrum disorders (ASD) by
Ishikawa-Brush et al. [Ishikawa-Brush et al.
(1997): Hum Mol Genet 6: 1241–1250]. Since this
original observation, only one association study
[Marui et al. (2004): Brain Dev 26: 5–7] has further
investigated, though unsuccessfully, the involve-
ment of the GRPR gene in ASD. With the aim of
contributing further information to this topic we
have sequenced the entire coding region and the
intron/exon junctions of the GRPR gene in 149
Italian autistic patients. The results of this study
led to the identification of four novel point
mutations, two of which, that is, C6S and L181F,
involve amino acid changes identified in two
patients with ASD and Rett syndrome, respec-
tively. Both the leucine at position 181 and the
cysteine at position 6 are strongly conserved in
vertebrates. C6S and L181F mutant proteins were
expressed in COS-7 and BALB/3T3 cells, but they
did not affect either GRP’s binding affinity or
its potency for stimulating phospholipase C-
mediated production of inositol 1,4,5-trispho-
sphate. In summary, our results do not provide
support for a major role of the GRPR gene in ASD
in the population of patients we have studied.
However, there is a potential role of C6S and
L181F mutations on GRPR function, and possibly
in the pathogenesis of the autistic disorders in the
two patients.  2008 Wiley-Liss, Inc.
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INTRODUCTION
Autism spectrum disorders (ASD; OMIM #209850) are
developmental disorders with complex phenotypes defined by
a triad of symptoms that include impaired social abilities,
deficient verbal and non-verbal communication skills, and
restricted interests with repetitive behaviors [APA, 2000]. The
underlying etiology remains largely unknown, yet ASD is one
of the most highly heritable of neuropsychiatric disorders
[Kates et al., 2004]. However, in only 10% of these patients has
a defined genetic disorder, either chromosomal or monogenic
[see Persico and Bourgeron, 2006 for a review], or a teratogen,
been identified as a likely etiological factor. Among monogenic
disorders, Rett syndrome (RTT; OMIM 312750) shares over-
lapping clinical features with autism, and clinical assessments
of social behavior have demonstrated a high frequency of
autism in Rett syndrome patients [Gillberg, 1986]. Rett
syndrome is an X-linked dominant neurodevelopmental dis-
order very often caused by mutations in the MECP2 gene
[Bienvenu et al., 2000] which encodes the methyl-CpG-binding
protein 2 (MeCP2). MECP2 mutations have also been found in
a few patients diagnosed with autism [Carney et al., 2003]
suggesting overlap also in the pathogenesis of these two
distinct genetic syndromes.
The gastrin-releasing peptide receptor (GRPR; chromosomal
location: Xp22.3-p21.2) is a member of the G protein-coupled
receptor superfamily containing seven transmembrane
domains. Gastrin-releasing peptide (GRP) binds to GRPR to
elicit a broad spectrum of biological effects on behavior,
digestion, and metabolism [see Roesler et al., 2006 for a recent
review]. Studies evaluating the role of GRPR in behavior and
synaptic plasticity in rodents indicate that GRPR’s in brain
limbic areas such as the amygdala and hippocampus are
involved in behaviors related to emotional responses, fear re-
lated learning, stereotypy and social interaction [Shumyatsky
et al., 2002]. Because the latter phenotypes are all features of
autism, the findings from rodent models also support the view
that the GRPR might be involved in the pathogenesis of
autism. Ten years ago the GRPR gene was proposed as a
candidate locus for infantile autism by Ishikawa-Brush et al.
[1997]. These authors detected an X-8 translocation, occurring
in the first intron of the GRPR gene, in a female patient with
multiple exostoses and autism accompanied by mental retar-
dation and epilepsy. A subsequent study performed in
Japanese patients by Marui et al. [2004] failed to detect
association of ASD with intragenic polymorphisms of the
GRPR gene. Surprisingly, with the exception of an additional
study [Heidary et al., 1998] who excluded the GRPR gene as a
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candidate locus for Rett syndrome, no other molecular genetic
studies have scanned the GRPR gene to search for mutations
potentially implicated in ASD. In this article we describe the
results of: (i) sequence analysis of the GRPR gene performed in
a cohort of 149 autistic patients (ii) the functional in vitro
expression analysis of two missense mutations identified in
two patients diagnosed, respectively, with ASD and RTT and
(iii) an association study carried out with intragenic poly-
morphisms.
PATIENTS AND METHODS
Patients
All patients (133 males and 16 females accounting for a male/
female ratio of 8.31:1, mean age 14.63 years; SD 5.85 years)
are mentally retarded and met DSM-IV-TR criteria [APA,
2000] for an autistic disorder. In addition, patients were
assessed by means of the (i) Childhood Autism Rating Scale
[CARS: Schopler and Dalldorf, 1980], (ii) Brunet–Lezine test
[Brunet and Le´zine, 1966], (iii) WISC-R test [Wechsler, 1974],
(iv) Psychoeducational Profile Revised (PEP-R) [Schopler
et al., 1990], (v) Griffith’s Mental Developmental Scales
[Griffiths, 1986], and (vi) Leiter International Performance
Scale [Leiter, 1979]. Patient A49 was also assessed by the
Vineland Adaptive Behaviour Scale [VABS: Sparrow et al.,
1984]. The two affected brothers of family A71 (A71A
and A71B), were also assessed by the Autism Diagnostic
Interview—Revised [ADI-R: Rutter et al., 2003], Autism
Diagnostic Observation Schedule—Generic [ADOS-G: Lord
et al., 2002] and by the Vineland Adaptive Behaviour Scale.
ADI-R and ADOS-G could be administered to a limited number
of patients because the, Author-approved, Italian versions of
these interviews were available less than 2 years ago.
Patients were excluded from this study if they displayed at
least one item from the following checklist: neurological focal
signs, chromosomal abnormalities detected by conventional
karyotyping, FMR1 gene mutation (fragile X syndrome), and
other neurological diseases such as phenylketonuria, neuro-
fibromatosis, tuberous sclerosis, encephalopathies due to
congenital infections, abnormal plasma and urine aminoacids
or abnormal urine mucopolysaccharides. Sicilian ancestry for
>95% of all patients was ascertained, for at least two
generations, by enquiring about the place of birth of their
maternal and paternal grandparents. Informed consent was
obtained from patients’ parents.
DNA Isolation and PCR Amplification of
the GRPR Gene Exons
Genomic DNA was isolated from peripheral blood lympho-
cytes according to standard procedures. Primer pairs, the
sequences of which are reported in supplementary Table IV,
were designed to amplify: (i) the coding region of exon 1, (ii) the
coding region and corresponding exon/intron junctions of exon
2 and (iii) the coding region of exon 3 of the GRPR gene. All PCR
reactions were performed in a 30 ml reaction volume contain-
ing: 75 ng of genomic DNA, 1 U of Taq Polymerase (GoTaq1
Promega, Madison, WI), 20 pmol of each primer, 0.2 mM of each
dNTP, 6 ml of a 5X Colorless GoTaq1Reaction Buffer (GoTaq1
Promega). PCRs were run for 30 cycles, each cycle performed as
follows: 948C for 30 sec, 598C for 30 sec, and 728C for 45 sec. The
reactions were terminated after an extension step at 728C for
5 min.
Site-Directed Mutagenesis
The pcDNA3.1_hGRPR plasmid contains the full-length
coding sequence of the GRPR gene. This plasmid was used to
generate a modified version of the GRPR cDNA containing the
sequence 50-GACUACAAGGACGACGAUGACAAG-30 which
encodes a FLAG epitope inserted between the last coding
triplet and the stop codon. This epitope was expressed at the
carboxy terminal end in the GRPR protein to be used as a tag
for antibody reaction. This modification was performed by the
QuikChange1 II Site-Directed Mutagenesis Kits (Stratagene,
La Jolla, CA) using primers MFLAGF and MFLAGR (see
Supplementary Fig. 3b). The resulting plasmid was named
pGRPR. Mutagenesis on the pGRPR plasmid, performed by the
protocol described above, was also used to generate: (i) plasmid
pGRPR_C6S containing mutation c.17G>C (C6S) and
(ii) plasmid pGRPR_L181F containing mutation c.541C>T
(L181F). The forward (F) and reverse (R) primers used to
introduce the missense mutations are M6F/M6R (C6S) and
M181F/M181R (L181F), their sequences are given in Supple-
mentary Figure 3b.
DNA Sequencing
All DNA samples were sequenced bidirectionally using the
ABI Prism Big Dye Terminator Cycle Sequencing Ready
Reaction Kit (vers. 1.1) and the ABI 310 Genetic analyzer
(Applied Biosystems, Foster City, CA). DNA fragments
amplified from genomic DNA were purified using Exonuclease
I and Shrimp Alkaline Phosphatase according to the manu-
facturer’s protocol (Exo-SAP kit Amersham Biosciences,
Uppsala, Sweden). Specific nested primers were used to
sequence the GRPR gene (named by the suffix ‘‘seq’’ in Supple-
mentary Table IV). Successful mutagenesis was checked by
priming the sequence reaction with oligonucleotides comple-
mentary to the ‘‘T7 promoter primer’’ and ‘‘BGH reverse
primer’’ sequences flanking the pcDNA3.1 polylinker (primers
sequences available at the Invitrogen, Carlsbad, CA, website).
In Silico Analysis
Comparison of the human GRPR protein sequence to the
orthologous sequence in other species was performed by the
TBLASTN software vers. 2.2.10 available at http://www.ncbi.
nih.gov/blast/ [Karlin and Altschul, 1990; Altschul et al., 1997].
Functional Analyses of wt and Mutant GRPR
Expressed in BALB 3T3 and COS-7 Cells
The following cells and materials were obtained from the
sources indicated: BALB 3T3 (mouse fibroblast) and COS-7
(monkey kidney) were from American Type Culture Collection
(ATCC; Manassas, VA); Dulbecco’s minimum essential
medium (DMEM), phosphate-buffered saline (PBS), Roswell
Park Memorial Institute (RPMI-1640), trypsin-EDTA and
fetal bovine serum (FBS), G418 sulfate from Life Technologies,
Inc. (Grand Island, NY); Na125I (2,200 Ci/mmol) and myo-
[2-3H] Inositol (20 Ci/mmol) were from Amersham Pharmacia
Bioscience, Amersham Place, UK; formic acid, ammonium
formate, disodium tetraborate, soybean trypsin inhibitor,
bacitracin, and AG1-X8 resin from Bio-Rad (Richmond, CA);
[Tyr4]bombesin ([Tyr4]Bn) and GRP were from Bachem
(Torrance, CA); and bovine serum albumin (BSA) from ICN
Pharmaceutical, Inc. (Aurora, OH).
BALB 3T3 or COS-7 cells were transfected with the wild-
type pGRPR or its mutants, pGRPR_C6S or pGRPR_L181F
DNA using the transfecting agent Fugene 6, and incubated for
24 hr at 378C in a 5% CO2 atmosphere. The cells were grown in
Dulbecco’s Modified Eagle’s cell medium (DMEM) supple-
mented with 10% FBS.
The 125I-[DTyr6, bAla11, Phe13, Nle14] Bn(6-14) radioligand,
with specific activity of 2,200 Ci/mmol, was prepared as
previously described [Mantey et al., 1997; Ryan et al., 1998].
Briefly, 0.8 mg of IOD-GEN solution (0.01 mg/ml in chloroform)
was added to a 5 ml plastic test tube, dried under nitrogen,
and washed with 100 ml of 0.5 M potassium phosphate solution
(pH 7.4). To this tube 20 ml of potassium phosphate solution
808 Seidita et al.
(pH 7.4), 8 mg of peptide in 4 ml of water, 2 mCi (20 ml) of Na125I
were added and incubated for 6 min at room temperature. The
incubation was stopped with 300 ml of water. The radiolabeled
peptide was separated using a Sep-Pak (Waters Associates,
Milford, MA) and further purified by reverse-phase high
performance liquid chromatography on a C18 column. The
fractions with the highest radioactivity and binding were
neutralized with 0.2 M Tris buffer (pH 9.5) and stored with
0.5% bovine serum albumin (w/v) at 208C.
Binding of 125I-Labeled BN-related peptides was performed
as described previously [Mantey et al., 1993, 1997]. The
standard binding buffer contained 24.5 mM HEPES (pH 7.4),
98 mM NaCl, 6 mM KCl, 5 mM MgCl2, 2.5 mM NaH2PO4, 5 mM
sodium pyruvate, 5 mM sodium fumarate, 0.01% (w/v) soybean
trypsin inhibitor, 1% amino acid mixture, 0.2% (w/v) bovine
serum albumin, and 0.05% (w/v) bacitracin. BALB 3T3 or COS-
7 cells transfected with the wild-type pGRPR or its mutants,
pGRPR_C6S or pGRPR_L181F were harvested, resuspended
(0.4 106/ml) in standard binding buffer and incubated at 228C
for 60 min with 50 pM 125I-labeled ligand (2,200 Ci/mol) and
varying concentrations of GRP. Aliquots (100 ml) were removed
and centrifuged through 300 ml of incubation buffer in 400 ml
microfuge tubes at 10,000g for 1 min using a Beckman Micro-
centrifuge B. The pellets were washed twice with buffer and
counted for radioactivity in a gamma counter. The non-
saturable binding was the amount of radioactivity associated
with cells in incubations containing 50 pM radioligand
(2,200 Ci/mmol) and 1 mM unlabeled ligand. Non-saturable
binding was <10% of total binding in all the experiments.
Receptor affinities were determined using the KaleidaGraph
software (SynergySoftware, Reading, PA).
Measurement of [3H] IP. Changes in total [3H] inositol
phosphates ([3H]IP) in cells transfected with the hGRPR or its
mutants were measured as described previously [Benya et al.,
1994; Schumann et al., 2003]. Briefly, COS-7 cells transfected
with the wild-type pGRPR or its mutants, pGRPR_C6S
or pGRPR_L181F were sub-cultured into 24-well plates
(5 104 cells/well) in regular propagation media and then
incubated for 24 hr at 378C in a 5% CO2 atmosphere. The cells
were then incubated with 3 Ci/ml of myo-[2-3H] inositol in
growth medium supplemented with 2% FBS for an additional
24 hr. Before assay, the cells in the 24-well plates were washed
by incubating for 30 min at 378C with 1 ml/well of PBS (pH 7.0)
containing 20 mM lithium chloride. The wash buffer was
aspirated and replaced with 500 ml of IP assay buffer
containing 135 mM sodium chloride, 20 mM HEPES (pH 7.4),
2 mM calcium chloride, 1.2 mM magnesium sulfate, 1 mM
EGTA, 20 mM lithium chloride, 11.1 mM glucose, 0.05% BSA
(w/v) and incubated with or without GRP, at concentrations
between 1 pM and 1 mM. After 60 min of incubation at 378C, the
experiments were terminated by the addition of 1 ml of ice cold
1% (v/v) hydrochloric acid in methanol. Total [3H]IP was
isolated by anion exchange chromatography as described
previously [Benya et al., 1994; Schumann et al., 2003]. Briefly,
samples were loaded onto Dowex AG1-X8 anion exchange resin
columns, washed with 5 ml of distilled water to remove free
[3H]inositol, then washed with 2 ml of 5 mM disodium
tetraborate/60 mM sodium formate solution to remove [3H]
glycerophosphorylinositol. Two milliliters of 1 mM ammonium
formate/100 mM formic acid solution were added to the
columns to elute total [3H]IP. Each eluate was mixed with
scintillation cocktail and measured for radioactivity in a
scintillation counter. Receptor potencies (EC50’s) were deter-
mined using a KaleidaGraph curve-fitting program.
Association Study
The frequency of mutations c.453C>T and c.663C>T and
derived haplotypes was compared between 149 autistic
patients (133 males and 16 females) and a sample of 106
‘‘non-autistic’’ male individuals (reference population) living in
the same geographic area (Sicily) to verify the hypothesis of a
genetic heterogeneity between ‘‘cases’’ and ‘‘controls.’’ The
group of 106 control males had a mean age of 55.53 years
(SD 16.96) and belong to the general population living in the
island of Sicily. Sicilian ancestry was ascertained for all
individuals of this reference population as described above
for the patients. Additional information on this reference
population can be found in Romano et al. [2003].
Statistical Analyses
The receptor affinities and potencies for the native GRPR
and mutant receptors were determined from the dose–
response curves using the least-squared, curve-fitting program
KaleidaGraph (SynergySoftware). Affinities and potencies of
the various receptors for a given agonist were compared using
the Mann–Whitney U-test and values which differed by
P< 0.05 were considered significant and reported. All affinities
and potencies are reported as meansSEM.
For the association study, the comparison between the
frequencies of the GRPR gene single nucleotide polymor-
phisms (SNPs) and corresponding haplotypes was performed
by the Chi-square test.
RESULTS
Case Reports for Patients A71A, A71B, and A49
Patient A71A is a 24-year-old male, the second born of non-
consanguineous parents. He has a brother affected by mental
retardation and an autistic disorder (A71B). At 18 months of
age he began to present social withdrawal and communication
impairment. A diagnosis of autistic disorder was made at the
age of 5 years. He came to our observation when he was
20 years old and at that time his cognitive and behavioral
phenotypes were reassessed. Cognitive test (LIPS) and
adaptive test (VABS) showed a severe mental retardation. IQ
according to LIPS is <30 and adaptive level expressed as Age
Equivalent, is 3.1. CARS scale gave a total score of 42.5. The
ADI-R and ADOS-G scores (see Table I) confirm the diagnosis
of AD in agreement with CARS and DSM-IV-TR criteria.
Patient A71B, the younger brother of A71A, is an 18-year-old
male. His psychomotor development was normal until the age
of 1 year, when an impairment in social interaction was
observed for the first time. At 1 year of age he also presented
with frequent stereotyped movements and hyperactivity.
Language development was reported as almost normal until
12 months of age, then it regressed. He came to our observation
TABLE I. ADI-R and ADOS-G Scores for A71A and
A71B Patient’s
Autism
cut-off
A71B
score
A71A
score
ADI-R
Social impairment
(SI)
10 23 23
Communication
(CO)
8 18 20
Repetitive behavior
(RB)
3 6 6
ADOS
Communication
(CO)
4 9 10
Reciprocal social
interaction (RSI)
7 12 14
RSIþCO 12 21 24
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at the age of 14 years. Cognitive test (LIPS) and adaptive test
(VABS) showed a severe mental retardation. According to
Leiter scale, IQ is <30 and adaptive behavior composite,
expressed as Age Equivalent, is 2.1. CARS scale gave a total
score of 43.5. The ADI-R and ADOS-G scores confirmed the
diagnosis of AD in agreement with CARS and DSM-IV-TR
criteria (see Table I). The patient displays self-injuring
behavior and trichotillomania.
Patient A49 is a 26-year-old female of non-consanguineous
parents. There is no family history of mental retardation,
autistic disorder or Rett syndrome. She has a younger healthy
brother. The patient came for the first time to our observation
at the age of 6 years. This patient was initially diagnosed with
autistic disorder and profound mental retardation according to
the criteria of DSM-IV-TR. The lack of significant improve-
ments of cognitive and adaptive performances even after
several years of a training program and a reassessment of the
behavioral phenotype strongly suggested a diagnosis of Rett
syndrome. This latter diagnosis was then confirmed by the
analysis of the MECP2 gene (see next paragraph).
Mutation Analysis of the GRPR and MECP2 Genes
The sequence analysis of the GRPR gene performed in 149
autistic patients overall uncovered six nucleotide changes all
within the coding region. In exon 2 mutation c.541C>T
leading to the missense mutation L181F was detected in a
heterozygote girl (Patient #A49) affected by Rett syndrome.
The analysis of the MECP2 gene in this patient indeed
confirmed she was heterozygote for the de novo mutation
R306C (see Fig. 1a). In an autistic boy (A71B) mutation
c.17G>C in exon 1 leading to the missense mutation C6S was
found. He inherited this mutation from his heterozygous
mother (see II-2 in Fig. 1b). In the same family (# 71) an autistic
brother (II-1) did not have this mutation. In the remaining
cases, only synonymous nucleotide changes were identified. In
particular, mutation c.93C>T was detected in one patient and
mutation c.396G>A was detected in another patient. These
four mutations have not been described previously. Finally, the
frequency of the alleles of two previously described SNPs
(c.453C>T and c.663C>T) [Heidary et al., 1998] were
determined in our autistic sample. A summary of all muta-
tions, with their frequencies, of the GRPR gene detected in both
patients and control individuals is reported in Table II.
In Silico and In Vitro Analyses
Our phylogenetic analysis showed that in vertebrates,
cysteine at position 6 and leucine at position 181 of the GRPR
protein are highly conserved (see Supplementary Fig. 4). In
particular, the Leu181 is embedded within the third extra-
cellular domain known to confer binding selectivity [Tokita
et al., 2002].
GRP had a high affinity for the hGRPR expressed in BALB/
3T3 cells (half maximal inhibitory concentration or IC50—
0.30 nM), a cell in which the human receptor as well as other Bn
receptors have been shown to function in an indistinguishable
manner from native receptor cells [Benya et al., 1992, 1994,
1995]. The affinity of GRP for either the pGRPR_C6S mutant or
the pGRPR_L181 mutant was not significantly different from
that for the wild-type GRPR expressed in BALB/3T3 cells
(Fig. 2, top panel, Table III). A similar result was seen when the
receptors were expressed in COS-7 cells: the wild-type,
pGRPR_C6S and pGRPR_L181F mutant receptors all have
affinities for GRP in the nanomolar range which were not
significantly different (Fig. 2, middle panel, Table III). The
wild-type pGRPR caused a 5.4-fold increase in [3H]IP release,
with an EC50 (half maximal effective concentration) in the low
Fig. 1. a: In family # A49 the daughter affected by Rett syndrome is
heterozygous for the MECP2 R306C de novo mutation and has inherited the
hGRPR L181F mutation from her father. N¼normal sequence; (b) hGRPR
genotypes detected in family # A71. Mutation C6S is transmitted from the
mother to only one (II-2) of the two autistic sibs. The symbol ‘‘Y’’ refers to the
Y chromosome.
TABLE II. hGRPR Gene Nucleotide Change and Haplotypes
Detected in the Autistic Sicilian Population and Controls
No. of X chromosomes (%)
Autistica Controlsb
Nucleotide changec
c.17G>C (C6S) 1/165 (0.6) 0/106 (0)
c.541C>T (L181F) 1/165 (0.6) 0/106 (0)
c.93C>T (N31N) 1/165 (0.6) 0/106 (0)
c.396G>A (T132T) 1/165 (0.6) 0/106 (0)
c.453C>T (S151S)* 115/165 (69.7) 79/106 (74.5)
c.663C>T (I221I)** 113/165 (68.5) 79/106 (74.5)
Haplotype***
c.453C–c.663C 50/165 (30.3) 27/106 (25.5)
c.453C–c.663T 0/165 (0) 0/106 (0)
c.453T–c.663C 2/165 (1.2) 0/106 (0)
c.453T–c.663T 113/165 (68.5) 79/106 (74.5)
Total 165 (100%) 106 (100%)
a133 males and 16 females.
b106 males.
cNamed according to Human Genome Variation Society nomenclature [den
Dunnen and Antonarakis, 2000; http://www.hgvs.org/mutnomen].
*w2 for case-control¼ 0.522, df¼ 1, P¼0.47.
**w2 for case-control¼ 0.87, df¼1, P¼ 0.35.
***w2 for case-control¼1.56; df¼ 2, P¼ 0.46.
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nanomolar range (i.e., 0.30 nM; Fig. 2, bottom panel, Table III).
GRP demonstrated a similar efficacy and potency for stimulat-
ing phospholipase C and increasing [3H]IP production in both
the pGRPR_C6S and pGRPR_L181F mutants to that seen in
the wild-type receptor (Fig. 2, bottom panel, Table III).
Association Study
The comparison of the frequency of the two most frequent
SNPs c.453C>T and c.663C>T between ‘‘cases’’ and ‘‘con-
trols’’ did not reveal statistically significant differences
(P¼ 0.47 and P¼ 0.35, respectively). Of the expected four
haplotypes only three were detected in the autistic population
and two in the general population (see Table II). Also for the
two most common haplotypes (C-C and T-T) the difference of
their frequency between ‘‘cases’’ and ‘‘controls’’ was not
significant (P¼ 0.46, see Table II). The two major SNPs
haplotypes (C-C and T-T) are different from the most likely
ancestral haplotype (T-C) as inferred by the comparison with
GRPR gene sequences of other Primates (Pan troglodytes and
Macaca mulatta).
DISCUSSION
The main aim of this study was to contribute new data to
assess the actual involvement of GRPR in ASD. To accomplish
this we have analyzed the entire coding sequence and intron/
exon splicing junctions of the GRPR gene in a population of 149
patients with ASD. This analysis allowed the identification of
four novel point mutations, two of which involve amino acid
changes, that is, C6S and L181F, in the protein sequence of
GRPR. The four newly identified alleles are absent in a sample
of 106 X chromosomes of unaffected individuals drawn from an
ethnically matched control population. The latter population
and the autistic population were also typed for two common
intragenic polymorphisms previously described by Heidary
et al. [1998] to detect the possible occurrence of genetic
heterogeneity between the two samples, but no evidence of
linkage disequilibrium was found, either for individual alleles
or for the corresponding four haplotypes. In family A71, the
presence of mutation C6S in only one (II-2 in Fig. 1b) of the two
affected brothers suggests that this mutation is not necessary
for the expression of ASD in this family.
In family A49, the presence of mutation L181F in the
unaffected (hemizygous) father excludes a major effect of this
mutation on the phenotype. However, these observations are
at least in theory still compatible with a postulated pathoge-
netic role of C6S and/or L181F of the hGRPR gene in the A49
Fig. 2. The ability of GRP to inhibit binding and stimulate an increase in
[3H]IP at the hGRPR or its mutants transiently expressed in BALB/3T3 cells
or COS-7 cells. For binding, Balb 3T3 or COS-7 cells transiently transfected
with the hGRPR or its mutants (0.4106 cell/ml) were incubated for 60 min
at 228C with 50 pM I125-[DTyr6, b-Ala11, Phe13, Nle14] Bn(6-14), with or
without the indicated concentrations of GRP added. Results are expressed as
the percentage of saturable binding without unlabeled peptide added
(percent control). To determine changes in [3H]IP, COS-7 cell transiently
transfected with hGRPR mutants were subcultured and preincubated for
24 hr at 378C with 3 mCi/ml myo-[2-3H]inositol. The cells were then
incubated with the GRP at the concentrations indicated for 60 min at 378C.
Values expressed are a percentage of total [3H]IP release stimulated by 1 mM
Grp. Control and 1 mM GRP stimulated values for hGRPR were 1,510 98
and 8,200 210 dpm, respectively. Results are the meanSEM from five
separate experiments, and in each experiment the data points were
determined in duplicate. All the P-values were not significant (i.e., well
above P< 0.05, in the P¼0.35–0.46 range). Pf17_hGRPR cell transfected
with pGRPR_C6S, Pf541_hGRPR cell transfected with pGRPR_L181F
(see text for additional details).
TABLE III. Affinity and Potency of GRP for the Wild-Type GRPR
and Two Mutant GRPR’s
GRPR receptor
Binding
(IC50, nM)
[3H]IP
(EC50, nM)
hGRPR/BALB
3T3 cells
hGRPR/
COS-7 cells
hGRPR/
COS-7 cells
Wild-type 0.300.02 0.71 0.03 0.30 0.02
GRPR C6S 0.250.01 1.05 0.06 0.63 0.06
GRPR L181F 0.160.01 0.42 0.01 0.44 0.03
IC50 and EC50’s are calculated from the data shown in Figure 2 and are the
means of five experiments. All the P-values were non-significant (i.e., well
above P<0.05, in the P¼0.35–0.46 range).
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and A71 families. Indeed, the genetic etiology of autism is likely
to be multifactorial in nature, that is, each single factor is not a
sufficient determinant of the phenotype [Persico and Bour-
geron, 2006]. Furthermore, genetic heterogeneity and/or low
penetrance may also account for the peculiar pattern of
genotype–phenotype relationship observed in the A49 and
A71 families.
Mutations C6S and L181F affect the first and third
extracellular (EC) domains, respectively, of the GRPR and
these EC domains are important regions of the receptor
because they are involved in selective agonist binding [Tokita
et al., 2001]. In particular the EC3 domain seems to be essential
for the Grp-ligand specificity [Tokita et al., 2002]. In order to
gain some insights on the potential role played by the two
amino acid substitutions on GRPR function, we first performed
a phylogenetic analysis which revealed that both leucine at
position 181 and cysteine at position 6 are strongly conserved
in vertebrates. This observation suggests that these two amino
acids are potentially important for proper functioning of
GRPR. In contrast, the C6S and L181F mutant proteins
expressed in COS-7 and BALB/3T3 cells did not affect either
the ligand binding or the second messenger production. The
signal transduction pathway analyzed in our experiments is
postulated to act, through the activated GRPR, by the catalysis
of guanine nucleotide exchange on Gaq to activate phospholi-
pase C-mediated production of inositol 1,4,5-trisphosphate
[Exton, 1996]. It is of course difficult to say whether the results
of our functional analysis reflect the effect of C6S and L181F
mutations on GRPR function in vivo. Studies performed in
recent years for example have shown that in addition to
eliciting the synthesis of classic second messengers (e.g., DAG
and IP3), the activated GRPR is also able to elicit cellular
responses using other members of the Gq family able to
transduct the signal along pathways that are different from
PLC [Rozengurt, 1998; Fan et al., 2005]. A fully reliable
interpretation of the effects of these mutations in vivo is also
hampered by the fact that most of our current knowledge on the
cellular signaling pathways for GRPR has been built up on
information gained by studying cancer and neuroendocrine
cell lines, not by studying neural cells.
In summary, our results do not provide support for a major
role of the hGRPR gene in ASD in the population of patients we
have studied. However, we cannot exclude that this negative
outcome was at least in part a consequence of misdiagnosis of a
(unknown) number of patients since only two of them were
clinically assessed by ADI-R and ADOS-G. On the other hand,
we suggest that a full understanding of the potential role of
C6S and L181F mutations on GRPR function, and possibly on
the pathogenesis of autistic disorder in the A71 and A49
patients should be postponed until we will have a better
understanding of the signaling pathways linked to this G
protein-coupled receptor, especially in neural cells.
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